Vertex Next Launches Global Data Centre & Cloud Expo Canada Exhibition & Conference. Rating 1 2 3 4 5; A strategic platform for digital infrastructure leaders to co ...

Vertex also announced that it's temporarily pausing the multiple ascending dose portion of its phase 1/2 study evaluating messenger RNA (mRNA) therapy VX-522 in treating cystic fibrosis (CF).

Vertex posted first-quarter adjusted earnings per share of $4.06, with revenue rising 3% year-over-year to $2.77 billion. Analysts surveyed by Visible Alpha were looking for $4.19 and $2.83 ...

Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% after the bell.

Vertex raises its full-year 2025 revenue guidance to a range of $11.85 billion to $12 billion versus estimates of $11.97 billion. Geopolitical tensions, Fed uncertainty, and fast-moving headlines ...

William Blair wrote,”We view the discontinuation of VX-264 as disappointing given that this would have expanded Vertex's type 1 diabetes market significantly from that being addressed from ...

If you need to move data from Excel into Calendar in Outlook regularly, you should consider automating the process to save time. I’m using Microsoft 365 Desktop on a Windows 10 64-bit system for ...

Investment on the rise Vertex’s results for the 2023 financial year show revenue of $9.9 billion, an increase of 11% from 2022 driven by Trikafta/Kaftrio for CF, which was up 16.4% to $8.9 billion.

Vertex reimbursed the research up to the termination of the deal, covering the costs of Verve’s work to identify and engineer specific gene editing systems and in vivo delivery systems directed ...

Vertex Pharmaceuticals' non-opioid painkiller received approval from the Food and Drug Administration. The drugmaker said the twice-daily pill, Journavx, is the first such treatment to hit the ...

Vertex has priced Alyftrek at a list price of $370,269 per year, which is 7% higher than Trikafta’s annual wholesale acquisition cost of $346,048, according to a securities filing.

Vertex, Inc., a leading provider of tax technology solutions, has been recognized as a Leader in three recent IDC MarketScape reports assessing SaaS and cloud-enabled tax automation software for ...